CN103006556A - Scutellarin nanosuspension and preparation method thereof - Google Patents
Scutellarin nanosuspension and preparation method thereof Download PDFInfo
- Publication number
- CN103006556A CN103006556A CN2012104294876A CN201210429487A CN103006556A CN 103006556 A CN103006556 A CN 103006556A CN 2012104294876 A CN2012104294876 A CN 2012104294876A CN 201210429487 A CN201210429487 A CN 201210429487A CN 103006556 A CN103006556 A CN 103006556A
- Authority
- CN
- China
- Prior art keywords
- scutellarin
- nanosuspension
- preparation
- stabilizing agent
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 title claims abstract description 108
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 title claims abstract description 108
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 title claims abstract description 105
- 229930190376 scutellarin Natural products 0.000 title claims abstract description 105
- 239000006070 nanosuspension Substances 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003381 stabilizer Substances 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000012670 alkaline solution Substances 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 5
- 229920003081 Povidone K 30 Polymers 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- -1 hydroxypropyl Chemical group 0.000 claims description 5
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims description 5
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 238000010008 shearing Methods 0.000 claims description 4
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 4
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 4
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- 238000001694 spray drying Methods 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000007517 polishing process Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 238000009700 powder processing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations, and relates to a scutellarin nanosuspension and a preparation method thereof. The scutellarin nanosuspension is prepared from a stabilizer and scutellarin in a weight ratio of (1:1)-(10:1). The preparation method is implemented through dissolving the scutellarin into an alkaline solution and then adding the obtained mixture into an acid solution containing the stabilizer, so that due to the solubility difference of the scutellarin in the acid solution and the alkaline solution, the scutellarin is oversaturated and then crystallized by separating; and carrying out homogenization on the obtained product by using a high-pressure micro jet homogenizer so as to obtain the scutellarin nanosuspension, wherein the particle size of the scutellarin nanosuspension is 100-500 nm, and the polydispersity index is 0.1-0.5. The scutellarin nanosuspension and preparation method thereof disclosed by the invention have the significant advantages that the nanosuspension improves the solubility of the scutellarin and increases the oral bioavailability of the scutellarin; the scutellarin nanosuspension can be solidified through freeze drying or spray drying, and applied to dosage forms such as tablets, capsules, granules, oral suspensions and the like; and the scutellarin nanosuspension is simple in preparation process, and convenient for industrial production.
Description
Technical field
The present invention relates to technical field of medicine, specifically a kind of scutellarin nanosuspension and preparation method thereof.
Background technology
Scutellarin is the main effective ingredient of breviscapine, chemistry Baicalein by name-7-O-β-D-Glucose aldehydic acid glycosides.Be mainly used in clinically treating the diseases such as paralysis after cerebral thrombosis, cerebral infarction, the apoplexy, coronary heart disease.Because scutellarin is insoluble in water almost, oral absorption is poor, and bioavailability is low, so greatly limited its application clinically.The Breviscapine of usefulness mainly contains tablet, injectable powder, injection etc. clinically at present.The conventional tablet oral administration biaavailability is low, and normal injection and injectable powder injection administration half-life are short, eliminate rapidly in the body.
For improving dissolubility and the bioavailability of scutellarin, the preparation work person solves this problem by many methods, has patent that breviscapine is made cyclodextrin clathrate (publication number CN 1739537A), injectable emulsion (publication number CN 1875981A), liposome (publication number CN 1444948A), drop pill (publication number CN1408392A), nano injection formulation (publication number CN 1879645A), albumin nano granular (publication number CN102415999A) etc.The related method of above patent has been improved dissolubility and the bioavailability of scutellarin in certain degree, but effect is still unsatisfactory.
The scutellarin nanosuspension can improve its dissolubility can improve its bioavailability again.The scutellarin nanosuspension is comprised of the scutellarin nanoparticle.Be different from other nanometer formulations, the scutellarin nanosuspension does not contain carrier material, only contain a small amount of stabilizing agent and keep scutellarin particle the stablizing in aqueous solution of nanoscale, drug loading is high, can reduce the administration volume, improve dissolution rate, have the intestinal adhesion, can prolong its holdup time in intestinal, improve its bioavailability.Report preparation scutellarin nanosuspension is not yet arranged at present.
The preparation method of nanosuspension mainly contains high pressure homogenization method, the sedimentation method, medium polishing, emulsion process etc.Medium polishing and emulsion process have organic solvent residual; The nanosuspension particle diameter of sedimentation method preparation is inhomogeneous, and polydispersity index is larger; High pressure homogenization method must be in advance with the drug powder processing.The sedimentation method can be used as the treatment step before the high pressure homogenize, prepare nanosuspension in conjunction with high pressure homogenization method, and its particle size distribution range is narrow, thereby obtains desirable nanosuspension.
Nanosuspension can directly be made oral administration mixed suspension, also can carry out dry solidification by lyophilization or spray drying, is applied to prepare tablet, capsule, granule.
Summary of the invention
The objective of the invention is in order to disclose a kind of scutellarin nanosuspension and its preparation method and application, prepared scutellarin nanosuspension can improve its dissolubility and bioavailability.
For achieving the above object, the present invention by the following technical solutions.
A kind of scutellarin nanosuspension, include scutellarin and stabilizing agent, described stabilizing agent and scutellarin weight ratio are 1:1 ~ 10:1, and described stabilizing agent is hydroxypropyl emthylcellulose K100, PVP K30, carboxymethyl starch sodium, PLURONICS F87, poloxamer F127, Tween 80, PEG400, Cremophor RH40 (polyoxyethylene hydrogenated Oleum Ricini 40), Cremophor EL (polyoxyethylene ether (35) Oleum Ricini), the Labrasol(Labraso), Gelucire 44/14 (Gelucire 44/14), the mixture of one or more Gelucire 50/13(stearic acid polyethyleneglycol glyceride).The particle diameter of scutellarin nanosuspension is 100nm ~ 500nm, and polydispersity index is 0.1 ~ 0.5.
Another object of the present invention provides the preparation method of above-mentioned scutellarin nanosuspension.
The technical scheme that realizes above-mentioned purpose is as follows:
A kind of preparation method of above-mentioned scutellarin nanosuspension may further comprise the steps:
(1) scutellarin is dissolved in the alkaline solution that pH value is pH6 ~ pH8, as good solvent; Described alkali
Property solution is a kind of in sodium hydrate aqueous solution, potassium hydroxide aqueous solution, the phosphate buffer;
(2) stabilizing agent is dissolved in the acid solution that pH value is pH1 ~ pH3, as poor solvent; Described acid solution is a kind of in aqueous hydrochloric acid solution, phosphate aqueous solution, the acetic acid aqueous solution;
(3) will be dissolved with the good solvent of scutellarin with in 0.5mL/min ~ 10mL/min adding poor solvent, dispersed with stirring, the method of dispersed with stirring adopts high shearing mixing emulsor stirring or mechanical agitation or magnetic agitation, the control mixing speed is at 100r/min ~ 1000r/min, add complete after, continue to stir 30min ~ 3h, form pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, controlled pressure is at 500bar ~ 1500bar, and cycle-index 2 times ~ 15 times makes nanosuspension.
The present invention is before employing high pressure microjet homogenizer prepares the scutellarin nanosuspension, the principle of the scutellarin crude drug being carried out pre-treatment is: scutellarin is dissolved in pH6 ~ pH8 alkaline solution as good solvent, contain the pH1 of stabilizing agent ~ pH3 acid solution as poor solvent, the good solvent that then will be dissolved with scutellarin joins in the poor solvent, utilize the dissolubility difference of scutellarin in good solvent and poor solvent, form supersaturated solution, cause the scutellarin crystallization, and under the effect of stabilizing agent the particle diameter of control scutellarin crystallization at nano-scale.
Adopt the high pressure micro jetting technology to prepare nanosuspension is mainly controlled medicine by regulating pressure and number of times particle diameter.Along with the increase of homogenization pressure and number of times, the obvious minimizing of the particle diameter of medicine and particle size distribution are more even.Controlled pressure is at 500bar ~ 1500bar, cycle-index 2 times ~ 15 times, and the scutellarin nanosuspension particle diameter of preparation is in 100nm ~ 500nm scope, and polydispersity index is 0.1 ~ 0.5.
Scutellarin nanosuspension of the present invention can improve the scutellarin dissolubility, improves the oral expenditure of making profits.The scutellarin nanosuspension can directly be made oral administration mixed suspension, also can be cured by lyophilization or spray drying, is used for several formulations form such as tablet, capsule, granule etc.
The specific embodiment
The specific embodiment of form is being described in further detail foregoing of the present invention by the following examples, but should not be interpreted as at this point that the scope of the above-mentioned theme of the present invention only limits to following example.
Embodiment 1:
In the described scutellarin nanosuspension of the present embodiment, stabilizing agent is 1.4g, wherein, comprises 0.8g PLURONICS F87 and 0.6g Cremophor EL; More than the scutellarin (purity is 90%(w/w)) be 0.3g, stabilizing agent: scutellarin is 4.7:1.
The preparation method of the described scutellarin nanosuspension of the present embodiment is as follows:,
(1) takes by weighing the 0.3g scutellarin, be dissolved in the 100mL phosphate buffer (pH7.4) as good solvent;
(2) get the 0.8g PLURONICS F87,0.6g Cremophor EL is dissolved in the 100mL phosphate aqueous solution (pH2.0) as poor solvent.
(3) the drip speed of good solvent with 0.5mL/min is splashed in the poor solvent, high shearing mixing emulsor dispersed with stirring, control mixing speed are dripped and are finished at 100r/min, continue to stir 1h, form pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, controlled pressure circulates 15 times at 800bar, makes nanosuspension.Detect with laser particle analyzer, mean diameter is 271.3nm, and polydispersity index is 0.2.
Embodiment 2:
In the described scutellarin nanosuspension of the present embodiment, stabilizing agent is 1g, comprises 0.4g PEG400 and 0.6g Labrasol; Scutellarin is 0.1g, stabilizing agent: scutellarin is 10:1.
The preparation method of the described scutellarin nanosuspension of the present embodiment is as follows:
(1) taking by weighing the 0.1g scutellarin is dissolved in the 100mL sodium hydroxide solution (pH6.8) as good solvent;
(2) get the 0.4g PEG400,0.6g Labrasol is dissolved in the 100mL aqueous hydrochloric acid solution (pH2.0) as poor solvent;
(3) the drip speed of good solvent with 5mL/min is splashed in the poor solvent, mechanical agitation is disperseed, and the control mixing speed is dripped and finished at 500r/min, continues to stir 30 minutes, forms pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, controlled pressure circulates 5 times at 1500bar, makes nanosuspension.Detect with laser particle analyzer, mean diameter is 161.4nm, and polydispersity index is 0.452.
Embodiment 3:
In the described scutellarin nanosuspension of the present embodiment, stabilizing agent is 1.5g, comprises 0.5g hydroxypropyl emthylcellulose K100 and 1gCremophor RH40; Scutellarin is 0.2g, stabilizing agent: scutellarin is 7.5:1.
The preparation method of the described scutellarin nanosuspension of the present embodiment is as follows:
(1) taking by weighing the 0.2g scutellarin is dissolved in the 100mL potassium hydroxide solution (pH7.5) as good solvent;
(2) get 0.5g hydroxypropyl emthylcellulose K100,1g Cremophor RH40 is dissolved in the 100mL acetic acid aqueous solution (pH3) as poor solvent;
(3) the drip speed of good solvent with 2mL/min is splashed in the poor solvent, magnetic agitation is disperseed, and the control mixing speed is dripped and finished at 800r/min, continues to stir 45min, forms pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, controlled pressure circulates 2 times at 1000bar, makes nanosuspension.Detect with laser particle analyzer, mean diameter is 331.7nm, and polydispersity index is 0.450.
Embodiment 4:
In the described scutellarin nanosuspension of the present embodiment, stabilizing agent is 2g, comprises 1g Tween 80 and 1g PVP K30; Scutellarin is 0.3g, stabilizing agent: scutellarin is 6.7:1.
The preparation method of the described scutellarin nanosuspension of the present embodiment is as follows:
(1) taking by weighing the 0.3g scutellarin is dissolved in the 100mL sodium hydroxide (pH7.0) as good solvent;
(2) getting 1g Tween 80 and 1g PVP K30 is dissolved in the 100mL phosphate aqueous solution (pH3.0) as poor solvent;
(3) the drip speed of good solvent with 4mL/min is splashed in the poor solvent, magnetic agitation is disperseed, and the control mixing speed is dripped and finished at 1000r/min, continues to stir 30min, forms pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, controlled pressure circulates 8 times at 1200bar, makes nanosuspension.Detect with laser particle analyzer, mean diameter is 199.1nm, and polydispersity index is 0.377.
Embodiment 5:
In the described scutellarin nanosuspension of the present embodiment, stabilizing agent is 1.5g, comprises 0.5gCremophor EL, 0.5g Gelucire 44/14 and 0.5g carboxymethyl starch sodium; Scutellarin is 0.3g, stabilizing agent: scutellarin is 5:1.
The preparation method of the described scutellarin nanosuspension of the present embodiment is as follows:
(1) taking by weighing the 0.3g scutellarin is dissolved in the 100mL phosphate buffer (pH7.4) as good solvent;
(2) get 0.5g Cremophor EL, 0.5g Gelucire 44/14, the 0.5g carboxymethyl starch sodium is dissolved in the 100mL aqueous hydrochloric acid solution (pH1.0) as poor solvent;
(3) the drip speed of good solvent with 1mL/min is splashed in the poor solvent, high shearing mixing emulsor dispersed with stirring, control mixing speed are dripped and are finished at 200r/min, continue to stir 1h, form pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, controlled pressure circulates 2 times at 500bar, makes nanosuspension.Detect with under the laser particle analyzer, mean diameter is 491.2nm, and polydispersity index is 0.489.
Embodiment 6:
Get scutellarin crude drug 2g and place 50ml water, in 25 ℃ of lower continuous stirring 48 hours, with 0.45 μ m filtering with microporous membrane, filtrate was diluted with an amount of methanol, with high effective liquid chromatography for measuring scutellarin concentration (Agilent 1200 type high performance liquid chromatographs, the DAD detector, Agilent Eclipse XDB C18 chromatographic column, mobile phase is acetonitrile: water: acetic acid=21:79:0.1, flow velocity is 1ml/min, the detection wavelength is 335nm, and 30 ℃ of column temperatures, sample size are 20 μ L).Other gets the scutellarin nanosuspension that makes among the embodiment 1 ~ 5 and operates with method, with high effective liquid chromatography for measuring scutellarin concentration (chromatographic condition is the same).Result such as table 1:
Table 1 scutellarin solubility experiment result
As seen, make nanosuspension after, the dissolubility of scutellarin has improved 5 ~ 12 times.
Embodiment 7:
Carry out animal drug disposition dynamic experiment take the scutellarin crude drug as matched group, investigate scutellarin nanosuspension absorption and the bioavailability in animal body that embodiment 1 makes.Method is with 12 of male SD rats, be divided at random two groups, every group 6, gavage gives scutellarin crude drug and scutellarin nanosuspension respectively, regularly gets blood from eye socket, after the processing, take rutin as interior mark, adopt the blood drug level of high effective liquid chromatography for measuring scutellarin, calculate pharmacokinetic parameters, the result is as shown in table 2:
Table 2 scutellarin animal pharmacokinetics experimental result
The result shows, compares with crude drug, and the maximum plasma concentration of scutellarin nanosuspension increases, and peak time shortens, and area under the drug-time curve significantly increases, and oral administration biaavailability significantly improves.
Embodiment 8:
Get the arbitrary nanosuspension that makes among the embodiment 1 ~ 5, add each 3% (weight ratio) of lactose and mannitol, the mix homogeneously lyophilizing gets buff powder.Get this powder an amount of, fully mix with other additive of tablet starch, carboxymethyl starch sodium, micropowder silica gel, magnesium stearate, by the specification of every 20mg scutellarin, full pressed powder obtains satisfactory scutellarin tablet.
Embodiment 9:
Get the arbitrary nanosuspension that makes among the embodiment 1 ~ 5, add 10% microcrystalline Cellulose, spray granulation behind the mix homogeneously.Then add 1% magnesium stearate, encapsulated by the specification of every 20mg scutellarin, obtain satisfactory scutellarin capsule.
Embodiment 10:
Get the arbitrary nanosuspension that makes among the embodiment 1 ~ 5, add in proportion 0.5% sodium carboxymethyl cellulose and 0.5% benzoic acid is received, by the specification packing of every 20mg scutellarin, obtain satisfactory scutellarin oral administration mixed suspension after mixing.
The above embodiment has only expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to claim of the present invention.Should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (8)
1. scutellarin nanosuspension, it is characterized in that, include scutellarin and stabilizing agent, described stabilizing agent and scutellarin weight ratio are 1:1 ~ 10:1, and described stabilizing agent is one or more the mixture among hydroxypropyl emthylcellulose K100, PVP K30, carboxymethyl starch sodium, PLURONICS F87, poloxamer F127, Tween 80, PEG400, Cremophor RH40, Cremophor EL, Labrasol, Gelucire44/14, the Gelucire 50/13.
2. scutellarin nanosuspension according to claim 1 is characterized in that, described stabilizing agent is the mixture of PEG400 and Labrasol; Or described stabilizing agent is the mixture of Tween 80 and PVP K30.
3. scutellarin nanosuspension according to claim 1 and 2 is characterized in that, the particle diameter of scutellarin nanosuspension is 100nm ~ 500nm, and polydispersity index is 0.1 ~ 0.5.
4. the preparation method of each described scutellarin nanosuspension of claim 1-3 is characterized in that, may further comprise the steps:
(1) scutellarin is dissolved in the alkaline solution of pH6 ~ pH8, as good solvent;
(2) stabilizing agent is dissolved in the acid solution of pH1 ~ pH3, as poor solvent;
The good solvent that (3) will be dissolved with scutellarin adds in the poor solvent, dispersed with stirring, adds complete after, continue stirring, form pre-nanosuspension;
(4) pre-nanosuspension is placed high pressure microjet homogenizer, make nanosuspension.
5. the preparation method of scutellarin nanosuspension according to claim 4 is characterized in that, described alkaline solution is a kind of in sodium hydrate aqueous solution, potassium hydroxide aqueous solution, the phosphate buffer.
6. the preparation method of scutellarin nanosuspension according to claim 4 is characterized in that, described acid solution is a kind of in aqueous hydrochloric acid solution, phosphate aqueous solution, the acetic acid aqueous solution.
7. the preparation method of each described scutellarin nanosuspension according to claim 4-6, it is characterized in that, step (3) is: the good solvent that will be dissolved with scutellarin adds in the poor solvent with 0.5mL/min ~ 10mL/min, dispersed with stirring, the method of dispersed with stirring adopts high shearing mixing emulsor stirring or mechanical agitation or magnetic agitation, and the control mixing speed is at 100r/min ~ 1000r/min, add complete after, continue to stir 30min ~ 3h, form pre-nanosuspension.
8. the preparation method of each described scutellarin nanosuspension according to claim 4-6, it is characterized in that, step (4) is: pre-nanosuspension is placed high pressure microjet homogenizer, and controlled pressure is at 500bar ~ 1500bar, cycle-index 2 times ~ 15 times makes nanosuspension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210429487.6A CN103006556B (en) | 2012-10-31 | 2012-10-31 | Scutellarin nanosuspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210429487.6A CN103006556B (en) | 2012-10-31 | 2012-10-31 | Scutellarin nanosuspension and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103006556A true CN103006556A (en) | 2013-04-03 |
| CN103006556B CN103006556B (en) | 2014-11-26 |
Family
ID=47956023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210429487.6A Expired - Fee Related CN103006556B (en) | 2012-10-31 | 2012-10-31 | Scutellarin nanosuspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103006556B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161724A (en) * | 2013-09-02 | 2014-11-26 | 郑州后羿制药有限公司 | Long-acting compound sulfamonomethoxine nanometer suspension and preparation method thereof |
| CN106265504A (en) * | 2016-09-29 | 2017-01-04 | 广东温氏大华农生物科技有限公司 | A kind of enrofloxacin nanosuspension and preparation method thereof |
| CN107982222A (en) * | 2017-12-01 | 2018-05-04 | 李文刚 | Breviscapinun freezes the preparation method of enteric coatel tablets or capsulae enterosolubilis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559424A (en) * | 2004-03-03 | 2005-01-05 | 复旦大学 | Erigeron breviscapus extraction dry suspensoid agent |
| CN102379886A (en) * | 2010-09-02 | 2012-03-21 | 昆明制药集团股份有限公司 | Scutellarin clinical preparation and preparation method thereof |
-
2012
- 2012-10-31 CN CN201210429487.6A patent/CN103006556B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559424A (en) * | 2004-03-03 | 2005-01-05 | 复旦大学 | Erigeron breviscapus extraction dry suspensoid agent |
| CN102379886A (en) * | 2010-09-02 | 2012-03-21 | 昆明制药集团股份有限公司 | Scutellarin clinical preparation and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| R.B.格普塔等主编，孙进等译，: "《纳米粒给药系统》", 30 April 2011, 科学出版社 * |
| SHE ZUO-YAN ET AL: "Preparation of Breviscapine Nanosuspension and its Pharmacokinetic Behavior in Rats", 《CHIN J NAT MED》 * |
| 汤丽华等，: "HPLC法测定灯盏乙素在不同PH值磷酸盐缓冲液中的溶解度", 《澳门科技大学学报》 * |
| 高缘等，: "黄芩素纳米混悬液的生物利用度研究", 《中国药科大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161724A (en) * | 2013-09-02 | 2014-11-26 | 郑州后羿制药有限公司 | Long-acting compound sulfamonomethoxine nanometer suspension and preparation method thereof |
| CN106265504A (en) * | 2016-09-29 | 2017-01-04 | 广东温氏大华农生物科技有限公司 | A kind of enrofloxacin nanosuspension and preparation method thereof |
| CN107982222A (en) * | 2017-12-01 | 2018-05-04 | 李文刚 | Breviscapinun freezes the preparation method of enteric coatel tablets or capsulae enterosolubilis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103006556B (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183426A (en) | Method of producing amorphous solid dispersion in submicron range by co-precipitation | |
| JP5215178B2 (en) | Formation of solid solutions based on low-solubility active substances by short-time heating and rapid drying | |
| CN102846543B (en) | Aripiprazole pharmaceutic preparation and preparation method thereof | |
| US20220031702A1 (en) | Solid Pharmaceutical Formulation of PARP Inhibitors and Use Thereof | |
| CN105902496A (en) | A treating method for a nanometer suspension solidification process | |
| Miura et al. | Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide | |
| CN105147607A (en) | Celecoxib nanosuspension and preparation method thereof | |
| CN104398477A (en) | Usnic acid nanometer suspension, and preparation method and use thereof | |
| CN107320460B (en) | Oral nilotinib nano preparation and preparation method thereof | |
| Dong et al. | Clay as a matrix former for spray drying of drug nanosuspensions | |
| EP2768485B1 (en) | Pharmaceutical nanosuspension | |
| CN101102740A (en) | Medicinal composition and process for producing the same | |
| CN103006556B (en) | Scutellarin nanosuspension and preparation method thereof | |
| CN104146975A (en) | Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate | |
| Coty et al. | Use of Spray Flash Evaporation (SFE) technology to improve dissolution of poorly soluble drugs: Case study on furosemide nanocrystals | |
| Varandal et al. | Different approaches toward the enhancement of drug solubility: A review | |
| EP3254699B1 (en) | Solid dispersion containing dutasteride, and composition containing same | |
| CN101961313B (en) | Itraconazole nanocrystals and preparation method and application thereof | |
| CN102908305A (en) | Dronedarone hydrochloride-containing oral solid medicinal composition and preparation method thereof | |
| CN100589801C (en) | Spray-dried granules containing pranlukast and processes for the preparation thereof | |
| MS et al. | Solubility enhancement techniques: A comprehensive review | |
| CN102048702B (en) | Bifendate nano crystal preparation and preparation method thereof | |
| TWI392507B (en) | Embedded micellar nanoparticles | |
| JP7481259B2 (en) | Spray drying process with continuous adjustment of the spray solution | |
| Choi et al. | Novel rivaroxaban-loaded microsphere systems with different surface microstructure for enhanced oral bioavailability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 Termination date: 20181031 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |